الفهرس 
Coronary Artery Bifurcation LesionsOnly 14 pages are availabe for public view
 |  | from | 143 |  |  |
| | | from | 143 | | |
Abstract
Interventions involving coronary artery bifurcation lesions are technically demanding and have been historically linked with lower procedural success rates and poorer clinical outcomes compared to non-bifurcation lesions, necessitating specialized preparation and distinct expertise. Drug-coated balloons (DCBs) have shown encouraging potential as a method for effectively managing the difficulties related to treating bifurcation lesions.
The objective of our research is to contrast the application of drug-coated balloons with that of conventional balloons in the provisional stenting of coronary artery bifurcation lesions, and to assess its influence on the procedural success rate and the incidence of short-term major adverse cardiac events (MACE).
The study is considered as an interventional clinical trial and is designed as a prospective study. Participants who fulfilled the inclusion criteria were recruited into our study and divided into two categories: group A: Patients who underwent provisional stenting using the traditional method with plain balloon angioplasty. group B: Patients who underwent provisional stenting using a drug-coated balloon.
Immediate outcomes for the patients were evaluated, and a clinical follow-up was conducted after a six-month period to monitor for major adverse cardiac events.
Our study indicate that Drug-coated balloons (DCBs) have surfaced as a compelling therapeutic strategy in the management of coronary bifurcation lesions. A substantial difference was noted between the case and control groups in relation to MACE after 6 months. The incidence of MACE was 22.5% (9 out of 40 patients) in the control group, compared to a mere 3.9% (1 patient) in the case group, with a p-value of 0.039. However, no significant difference was discerned between the two groups regarding in-hospital MACE in this study.